Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CXCL10/CXCR3-based prediction of postoperative delirium and Dragon’s Blood combined intervention
ChiCTR2600118658Phase 4Not yet recruiting
- Sponsor
- Jiaxing Second Hospital
- Start
- Feb 2026
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of resina draconis in postoperative delirium (POD) and Postoperative neurocognitive disorder (PND) (5 arms), sponsored by Jiaxing Second Hospital. Primary endpoints: Peripheral blood levels of CXCL10 and Incidence of postoperative delirium. Planned start Feb 2026; status: not yet recruiting.
02
Drugs
resina draconis
03
Conditions
postoperative delirium (POD)Postoperative neurocognitive disorder (PND)
Beyond the preview
Go deeper on ChiCTR2600118658.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600118658.